Liviu Hîțu’s Post

New issue online!🌿 Unveiling CXCR2 as a promising therapeutic target in #renalcellcarcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001 ----------------------- In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. This study by Gilles Pagès, Maeva Dufies et al. explored the potential of enhancing ccRCC treatment by concurrently using CXCR2 inhibitors alongside immunotherapies. Read here⤵️ https://lnkd.in/dBWfcbc7 #Tumorassociatedmacrophages #Immunotherapiesresistance #CXCR2inhibitors #Nivolumab #Ipilimumab IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

#Ribociclib was approved by the FDA for stage II/III ER+ breast cancer in the adjuvant setting in combination with endocrine therapy. This is 2nd CDK4/6 inhibitor in the setting ! Very small benefit shows 5% improvement in DFS at 4 yrs. The differences compared to abemcicilib: 📍3 year duration vs. 2 yrs 📍intermittent 3 weeks on, 1 off, not continuous 📍includes more patients including some with node negative disease 📍less diarrhea than abema, but more neutropenia 📍need for ECG ❤️ monitoring at baseline and at day 15 (cycle 2 ECG no longer needed unless risk factors), need for LFT monitoring (this isn't an insignificant % of pts and needs to be closely watched 👀 ) 📍Lower dose of ribo in adjuvant setting (400mg vs. 600 mg in metastatic, abema dose is the same across early and metastatic) Update was presented #ESMO24 just this week and shows 5% improvement in DFS at 4 yrs. just like #abema the benefit has increased every time we look at updated data.

Get #genomic insights to help early -stage HR+, HER2- #breastcancer patients understand if they benefit from #chemotherapy. Treat with even more confidence with the #OncotypeDX test:

Get #genomic insights to help early -stage HR+, HER2- #breastcancer patients understand if they benefit from #chemotherapy. Treat with even more confidence with the #OncotypeDX test:

Treatment with benmelstobart and anlotinib yielded a superior PFS and ORR vs sunitinib in patients with advanced renal cell carcinoma, according to data from the phase 3 ETER100 trial. #ESMO24 https://lnkd.in/edcgeFPS

The latest in ACP #Gastroenterology Monthly: http://ow.ly/EneC50HcMkX 🔸 IV iron appears safe, effective for bleeding-related iron-deficiency anemia in cirrhosis 🔸 GLP-1s associated with lower risk of hepatic decompensation than other diabetes drugs 🔸 Colectomy linked with greater risk of AKI, kidney failure in patients with IBD 🔸 Spotlight on colorectal cancer screening intervals

🌟🌟 Glofitamab has been approved to treat relapsed or refractory large B-cell lymphomas! 🎗️🌟 Large B-cell lymphomas are a type of non-Hodgkin's lymphoma (NHL), a cancer that affects the lymphatic system, a vital component of our immune system. Large B-cell lymphoma is the most frequent type of lymphoma and accounts for about 25-30% of all NHLs. These lymphomas are distinguished by aberrant B-cell development, a type of white blood cell responsible for protecting the body from infections. 💪❤️ Glofitamab (Columvi, Genentech, Inc.) received accelerated approval from the U.S. Food and Drug Administration on June 15, 2023. It is based on the outcomes of the Phase I/II NP30179 study, which confirmed significant and durable responses in patients with relapsed or refractory large B-cell lymphomas. 🙌🏼💙 Dive into the details of Glofitamab and explore the revolutionary significance of its accelerated approval by reading our blog @ https://lnkd.in/gSq-Mt_S 🌍👩⚕️👨⚕️ #Glofitamab #MedicalBreakthrough #CancerTreatment #HopeInHealthcare #AcceleratedApproval #InnovationInMedicine #LymphomaTreatment #MedicalAdvancements #CancerResearch #HealthcareHeroes #MedicalMilestone #BCellLymphomas #BispecificAntibody #TCellEngager #NonHodgkinsLymphoma #ImmunologicalSynapse #EarlyDiagnosis #Bhimar #LifeSciences #Healthcare #Informations #Omics #Surgery #Radiotherapy #Chemotherapy #Immunotherapy

It is also known as metastatic breast cancer and is considered an advanced stage of the disease. Read more 👉 https://lttr.ai/ARfa2 #Cdk46Inhibitor #AromataseInhibitors #HormoneReceptorPositive #Pharmacist #Healthcare #Quality #Chemotherapy #GenomicComplexityDetected #BloodCopyNumberBurden #PredictPoorOutcomes

Ivonescimab in combination with chemotherapy showed promising anti-tumor activity as 1L treatment of TNBC.  − ORR was 72.4%, DCR was 100%, median PFS was 9.3 month (6.24, NE). − In CPS<10 population, ORR was 69.6%, median PFS was 9.3 month (5.55, NE). Ivonescimab in combination with chemotherapy demonstrated a manageable safety profile in locally advanced unresectable or metastatic TNBC.  − The most common TRAEs were hematologic abnormalities and liver enzyme abnormalities, with the      majority being grade 1-2.  −No TRAEs that led to permanent treatment discontinuation or death. #TNBC #breastcancer #ivonescimab #akeso #bispecific https://lnkd.in/g73u_mjj

𝙐𝙣𝙙𝙚𝙧𝙨𝙩𝙖𝙣𝙙𝙞𝙣𝙜 𝙩𝙝𝙚 𝙧𝙞𝙨𝙠 𝙛𝙖𝙘𝙩𝙤𝙧𝙨 𝙖𝙨𝙨𝙤𝙘𝙞𝙖𝙩𝙚𝙙 𝙬𝙞𝙩𝙝 𝙝𝙚𝙖𝙙 𝙖𝙣𝙙 𝙣𝙚𝙘𝙠 𝙘𝙖𝙣𝙘𝙚𝙧 𝙞𝙨 𝙘𝙧𝙪𝙘𝙞𝙖𝙡 𝙛𝙤𝙧 𝙥𝙧𝙚𝙫𝙚𝙣𝙩𝙞𝙤𝙣 𝙖𝙣𝙙 𝙚𝙖𝙧𝙡𝙮 𝙙𝙚𝙩𝙚𝙘𝙩𝙞𝙤𝙣. 𝙎𝙩𝙖𝙮 𝙞𝙣𝙛𝙤𝙧𝙢𝙚𝙙 𝙖𝙣𝙙 𝙨𝙩𝙖𝙮 𝙫𝙞𝙜𝙞𝙡𝙖𝙣𝙩. If you have any symptoms, must visit to Oncologist. To book an appointment with Dr Deepak Singla, Medical Oncologist, 𝐜𝐚𝐥𝐥 𝐧𝐨𝐰 𝐚𝐭 𝟖𝟔𝟗𝟗𝟗𝟎𝟒𝟓𝟗𝟗. #swastikcancerclinic #drdeepaksingla #oncologist #bestdoctorintricity #cancerscreeningtest #cancerpatient #cancertreatment #cancerprevention #cancerclinic #cancerfighter #prostatecancertreatment #prostatecancerawareness #prostatecancer #chemotherapy #coloncancertreatment #coloncancersymptoms #colorectalcancerawareness #multiplemylomacancer #multiplemyeloma #headandneckcancer #headandneckcancersymptoms #headandneckcancertypes #riskfactorsofheadandneckcancer #headandneckcancer #cancerprevention